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Abstract
Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein
with low pI (Smac/DIABLO) is a proapoptogenic mitochondrial protein that is released to the
cytosol in response to diverse apoptotic stimuli, including commonly used chemotherapeutic drugs.
In the cytosol, Smac/DIABLO interacts and antagonizes inhibitors of apoptosis proteins (IAPs), thus
allowing the activation of caspases and apoptosis. This activity has prompted the synthesis of
peptidomimetics that could potentially be used in cancer therapy. For these reasons, several
authors have analyzed the expression levels of Smac/DIABLO in samples of patients from different
tumors. Although dissimilar results have been found, a tissue-specific role of this protein emerges
from the data. The objective of this review is to present the current knowledge of the Smac/
DIABLO role in cancer and its possible use as a marker or therapeutic target for drug design.
Background
Cancer cells share six features that distinguish them from
normal cells: Autocrine production of growth signals, ina-
bility to respond to anti-growth signals, sustained angio-
genesis, limitless replicative potential, tissue invasion and
metastasis, and apoptosis avoidance [1]. This type of cell
death is fundamental for the maintenance of tissue home-
ostasis and immune system development [2]. Tumor cells
are subjected to stressful internal and external environ-
ments, but nevertheless are resistant to apoptosis.
Apoptosis can be activated through two pathways: The
extrinsic pathway (mediated by death receptors) or the
intrinsic pathway (mediated by mitochondria). The
former is activated in response to the engagement of lig-
ands such as CD95 or TNF-α with their receptors. This in
turn induces the recruitment of adapter proteins (FADD,
TRADD o RAIDD) to form the so-called death-inducing
signal complex (DISC), which activates caspase-8. In turn,
caspase 8 activates effector caspases by catalytic cleavage.
The intrinsic pathway is induced by several different stim-
uli like antineoplastic drugs, hypoxia, irradiation, growth
factor withdrawal and heat shock. These stimuli provoke
the mitochondrial outer membrane permeabilization
(MOMP) and the release of proteins from the intermem-
brane space, such as cytochrome-c, Smac/DIABLO, Omi/
HtrA2 and AIF to the cytosol [3]. This release allows the
assemble of a multiprotein complex, the apoptosome,
that includes cytochrome-c, procaspase-9, dATP and
cytosolic apoptosis inductor factor-1 (Apaf-1) [4]. The
Published: 26 September 2008
Journal of Experimental & Clinical Cancer Research 2008, 27:48 doi:10.1186/1756-9966-27-48
Received: 14 August 2008
Accepted: 26 September 2008
This article is available from: http://www.jeccr.com/content/27/1/48
© 2008 Martinez-Ruiz et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Experimental & Clinical Cancer Research 2008, 27:48 http://www.jeccr.com/content/27/1/48
Page 2 of 7
(page number not for citation purposes)
apoptosome activates caspase-9, which in turn induces
the activation of effector caspases-3, -6 and -7 [5]. The
effector caspases cleave their cellular specific substrates
and generate the typical morphology of apoptosis.
The activity of mature caspases is negatively regulated by
their interaction with inhibitor of apoptosis proteins
(IAPs) [6,7]. This protein family is comprised by X-linked
inhibitor of apoptosis (XIAP), cellular IAP-1 (c-IAP1), cel-
lular IAP-2 (c-IAP2), Testis specific IAP (Ts-IAP), survivin,
livin and BRUCE/Apollon [8]. The more studied member
is XIAP, formed by three BIR (Baculoviral IAP Repeat)
domains located in the NH2-terminus and one RING
(Really Interesting New Gene) domain in the CO2H-ter-
minus. The linker region between the BIR1 and BIR2 is
implicated in the inhibition of caspase-3 and -7 whereas
the BIR2 domain inhibits caspase-7 in a non-competitive
manner [9]. Caspase-9 activity is inhibited by its associa-
tion with the BIR3 domain of XIAP [10]. In addition, it
has been determined that the RING domain of XIAP has
E3 ubiquitin ligase activity toward caspases, provoking
their degradation by the proteasome after their interaction
[11,12].
Smac (Second mitochondria-derived activator of caspase)
protein, also known as DIABLO (Direct Inhibitor of
Apoptosis-Binding protein with LOw pI), is codified by a
nuclear gene. Its protein presents an NH2-terminus that
serves as mitochondrial targeting signal (MTS). The
mature form of Smac/DIABLO is originated by the cleav-
age of this signal. In the presence of apoptotic stimuli,
mature Smac/DIABLO is release to the cytosol [13]. There,
Smac/DIABLO has a pro-apoptotic effect that is mediated
by its interaction with IAPs and the release of caspases
from them. Structural data had established that Smac/
DIABLO requires to form homodimers to interact with
IAPs [14]. A particular NH2- terminal motif, consisting of
four amino acids, Ala-Val-Pro-Ile, is responsible for the
interaction with IAPs [14,15]. It has been demonstrated
that Smac/DIABLO interacts with the BIR2 and BIR3
domains of XIAP, allowing the release of caspase-3 [14]
and caspase 9 [16], respectively. Caspase-9 has a similar
tetrapeptide motif in its NH2-terminus, so both compete
for the BIR3 domain of XIAP [15]. Capase-3 is released by
the interaction between NH2-terminus of Smac/DIABLO
and BIR2 domain of XIAP [17].
Smac/DIABLO sensitizes tumor cells to die by apoptosis
Several studies have shown that overexpression of Smac/
DIABLO sensitizes neoplastic cells to apoptotic death
[18,19]. These findings prompted the development of
peptides derived from NH2-terminal of smac/DIABLO
and small molecules that mimic Smac/DIABLO functions
as therapeutic agents in order to induce death or to
increase the apoptotic effect of chemotherapeutic agents.
Permeable NH2-terminal peptides of Smac/DIABLO sen-
sitize Hodgkin lymphoma cells to apoptosis mediated by
B granzyme [18] and induce caspase-3 activation medi-
ated by cytochrome- c [19]. Moreover, NH2-terminal pep-
tides of Smac/DIABLO fused to Drosophila
antennapaedia penetratin sequences enhance apoptosis
mediated by different antineoplastic agents in breast can-
cer [20] and glioblastoma cell lines [21]. Similarly, a small
Smac-mimic compound is able to increase the apoptotic
effects of death factors such as TRAIL and TNF-α [22]. It is
interesting to note that this small molecule induces apop-
tosis by itself in MDA-MB-231 breast cancer cells, which
have high expression levels of XIAP and c-IAP1. In con-
trast, it only sensitizes MDA-MB-452 and T47D cells,
which have low IAPs expression, to TRAIL or etoposide.
[23]. Recently, it has been described that compounds that
mimic Smac/DIABLO induce the activation of the NF-kB
pathway eliciting TNF-α-dependent apoptosis via caspase-
8 activation [24]. This activation depends on c-IAP1 and -
2 degradation [25]. This was replicated in vivo using a
malignant glioma xenograft mice model, in which co-
administration of Smac/DIABLO peptides and TRAIL sen-
sitized glioma cells to apoptotic death and induced tumor
regression [26]. In the same line, tumor regression was
observed when nude mice with xenografted hepatocarci-
noma tumors where locally treated with an adenovirus
expressing Smac/DIABLO and 5-Fluorouracyl [27]. Taken
together, these results show that the NH2-terminal Smac/
DIABLO derivatives and small molecules that mimic its
function could be useful as adyuvant therapy in tumors
with low levels of IAPs and as stand-alone therapy in
tumors with high expression of IAPs. Further work is
needed to address the potential use of these drugs in
humans. Nevertheless, these studies show that particular
expression levels of IAPs are key to the cellular response to
these peptides or small molecules and underline the posi-
ble contribution of Smac/DIABLO levels to the intrinsic
resistance to antineoplastic drugs.
Smac/DIABLO and cancer progression
Due to the importance of Smac/DIABLO in determining
the sensitivity of cancer cells to apoptotic death induced
by diverse stimuli, it is important to investigate if its
expression levels could be negatively regulated during the
initiation or progression of cancer. This information
could be useful as a prognostic or therapeutic marker or to
provide new targets for drug design. As mentioned before,
it could be expected that cells with lower Smac/DIABLO
and therefore, higher apoptosis resistance, should be
selected during cancer progression. This selection would
contribute to the higher intrinsic resistance in more
advanced cancer stages. All the studies have been summa-
rized in Table 1.Journal of Experimental & Clinical Cancer Research 2008, 27:48 http://www.jeccr.com/content/27/1/48
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Inverse correlation between Smac/DIABLO expression and 
cancer progression
Two recent studies of Renal Cell Carcinoma (RCC)
patients showed that Smac/DIABLO expression at both
mRNA and protein level were not associated with stage or
grade of tumor [28,29]. However, another study demon-
strated a significative inverse correlation between Smac/
DIABLO protein expression level and both stage and his-
tologic grade of RCC [30]. Regardless of this discrepancy,
a clear correlation with progression was made in the three
studies: patients with metastasic disease had lower Smac/
DIABLO levels than those with localized disease [28-30].
In addition, it was shown that patients that undergo radi-
cal nephrectomy for RCC with positive Smac/DIABLO
expression had a longer disease-specific survival when
compared with those with negative expression [30]. More-
over, RCC patients with low Smac/DIABLO expression
had a four times higher risk to die than those with high
expression [29].
Similarly, Sekimura et al have shown that Smac/DIABLO
mRNA levels decreased significantly during lung cancer
progression [31]. Since it has been shown that IAPs levels
are upregulated in non small cell lung cancer [32], this
reduction should increase further the apoptotic threshold
of these cells. As expected from these results, decreasing
XIAP expression in vitro sensitized lung cancer cells to
apoptosis induced by diverse stimuli [33].
It has also been shown that testicular germ tumors with
more advanced malignant phenotype presented lower
Smac/DIABLO expression levels [34]. Moreover, the
XIAP-Smac/DIABLO ratio increased significatively in clin-
ical stage III tumors when compared with stages I or II. In
this study an inverse correlation between Smac/DIABLO
expression levels and cancer progression was also demon-
strated [34].
Finally, it has also been shown that Smac/DIABLO mRNA
and protein expression is reduced in hepatocellular carci-
noma (HCC) when compared with normal hepatic tissue
[35]. This reduction directly correlated with progression.
Moreover, in this study, the authors showed that the IAP
survivin, increased in parallel with cancer progression
[35]. All these studies showed that Smac/DIABLO expres-
sion inversely correlated with cancer progression, aggres-
Table 1: Expression of Smac/DIABLO in different tumors.
Tumor Smac/DIABLO
 expression
Molecule analyzed Disease relationship. Ref.
RCC ↓ mRNA. Expression was low in patients with metastasis 
progress.
[29]
↓ Protein. The levels of expression inversely correlate with grade 
disease.
[30]
- mRNA and protein. XIAP-Smac/DIABLO ratio increased from early 
to advance stages.
[28]
Lung cancer ↓ mRNA. Patients with low expression had worse prognosis. [31]
TGCT ↓ mRNA. Smac/DIABLO expression diminished from 
normal testicular tissue to non-seminomatous 
germ cell tumours and stage III tumors.
[34]
HCC ↓ mRNA and protein. Tissues with HCC primary had low expression of Smac/
DIABLO compared with normal organ.
[35]
CC ↑ mRNA. Smac/DIABLO expression is independent of 
stage. In a subset of tumors Smac/DIABLO is 
expressed de novo.
[36]
↑ Protein. Higher expression in adenocarcinoma than squamous 
tumors and correlates with a marker of angiogenesis.
There was not any correlation with grade disease or 
survival rates.
[37]
GA ↑ mRNA. Smac/DIABLO expression was higher in gastric 
adenocarcinomas than in non-neoplastic gastric 
mucosa.
[38]
Lymphomas (NHL and HL) - Protein. There was not difference in Smac/DIABLO expression 
between clinically indolent and aggressive NHLs.
Ren. Y. et al.*
Carcinomas and sarcomas - Protein. Different tumors had distinct immunoreactivity 
against Smac/DIABLO.
Yoo, N.J.et al**
*Y. Ren, N. Akyurek, E. Schlette, G.Z. Rassidakis, and L.J. Medeiros, Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. 
Hum Pathol 37 (2006) 1407-13., ** N.J. Yoo, H.S. Kim, S.Y. Kim, W.S. Park, C.H. Park, H.M. Jeon, E.S. Jung, J.Y. Lee, and S.H. Lee, 
Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. Apmis 111 (2003) 382-8.
Abbreviations: RCC, Renal Cell Carcinoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; HCC, Hepatocellular carcinoma; CC, Cervical 
cancer; GA, Gastric adenocarcinoma; TGCT, Testicular germ cell tumors; XIAP, X-linked IAP.Journal of Experimental & Clinical Cancer Research 2008, 27:48 http://www.jeccr.com/content/27/1/48
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sive behavior, as shown by metastasic disease, and bad
prognosis. These correlations could be due to an increased
apoptotic threshold, which should allow cancer cells to
withstand not only invasion and metastasis, but to pro-
vide a relative increased intrinsic resistance to chemo- or
radiotherapy. Further in vivo experiments specific for each
tumor should help to solve this question.
Direct correlation between Smac/DIABLO expression and 
cancer progression
Recently, our group analyzed the participation of Smac/
DIABLO in cervical cancer patients. Surprisingly, we
found that Smac/DIABLO expression did not correlate
inversely with progression. As a matter of fact, normal cer-
vix barely expressed the Smac/DIABLO RNA messenger.
During cancer progression, a subset of cervical cancer
samples expressed de novo this protein [36]. We could not
find any correlation between Smac/DIABLO expression
and stage or grade for both squamous cell carcinoma and
adenocarcinoma [37]. However, higher immunostaining
was directly associated with local recurrence in squamous
cell carcinoma. We also established a positive correlation
between Smac/DIABLO immunoreactivity and high
microvascular density [37], which could be accounting for
the recurrence results. More investigation is needed to
clarify the relation between Smac/DIABLO and angiogen-
esis in cervical cancer.
A similar finding in gastric cancer patients supports these
results [38]. Gastric adenocarcinomas showed a signifi-
cant higher expression of Smac/DIABLO than non-neo-
plastic gastric mucosa [38]. However, no difference in the
ratio XIAP-Smac/DIABLO between non-neoplasic gastric
mucosa and gastric adenocarcinoma was found [38]. This
discrepancy could be due to decrease in the expression of
XAF1 (XIAP-associated factor-1) found in these samples
[38]. XAF1 is a direct inhibitor of XIAP, so this decrease
could be also be increasing the apoptotic threshold of
these tumors [39]. Supporting these results, a recent
report showed that a decrease of XIAP in gastric cancer
cells increase the apoptotic response induced by cisplatin
and mitomycin-c [40].
Analyzing a single protein such as Smac/DIABLO or a par-
ticular IAP in cancer samples, will only give a partial
vision of the mitochondrial apoptotic threshold, since it is
known that these proteins are regulated by themselves
and, in a tissue-specific pattern, specific IAPs functions
overlap. In the case of IAPs (Figure 1), although Smac/
DIABLO is not able to degradate XIAP, it induces the ubiq-
uitination and degradation of other members of the fam-
ily, such as c-IAP1 and c-IAP2 [41]. In addition, a recently
cloned Smac/DIABLO isoform, Smac3, induces the auto-
ubiquitination and degradation of XIAP [42]. As men-
tioned before, another negative regulator of XIAP is XAF1.
This protein antagonizes the inhibitory activity of XIAP
toward caspase-3 [39]. Similarly to IAPs, Smac/DIABLO is
also regulated by IAPs family members (Figure 2). Livin is
able to ubiquitinate and degrade Smac/DIABLO [43].
Also, in a reciprocal manner, XIAP, c-IAP1, c-IAP2 and
Apollon induce the ubiquitination and degradation of
Smac/DIABLO [11,44,45]. Although in vivo relevance has
not yet been demonstrated for these mechanisms, a com-
plicated scenario emerges from these studies, underlying
the need for more research focusing not only in Smac/
DIABLO protein and isoforms, but also in their interac-
tion partners in a tissue-specific manner.
Conclusion
The balance of IAPs and Smac/DIABLO dictates the apop-
totic response to microenvironment clues (e.g. invasion
and metastasis) and therapy. Due to this, it is important
to perform protein expression studies, which are more
informative than mRNA expression analyses, to survey
not only Smac/DIABLO but also IAP family members to
establish the relevance of these molecules in cancer pro-
gression and as possible prognostic markers. Although
there is much to learn, we believe that directed therapy
aimed to inhibit IAPs functions could be more efficient in
those cancers with IAP overexpression or low expression
of Smac/DIABLO. Nevertheless, caution is needed in
those tumors in which the Smac/DIABLO and IAPs asso-
ciation with progression and/or prognosis is not clear,
such as cervical and gastric cancer.
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Smac/DIABLO and other proteins are able to regulate the expression levels of inhibitors of apoptosis (IAPs) Figure 1
Smac/DIABLO and other proteins are able to regulate the expression levels of inhibitors of apoptosis (IAPs). 
Smac/DIABLO-induced downregulation of c-IAP1 and c-IAP2 is mediated by ubiquitination and proteasomal degradation. 
Smac3, a Smac/DIABLO isoform generated by alternative splicing, induces the auto-ubiquitination and degradation of XIAP by 
the proteasome. Omi/HtrA2 degradates XIAP, c-IAP1 and c-IAP2. Another negative regulator of XIAP is XAF1.
The inhibitors of apoptosis (IAPs) regulate expression levels of Smac/DIABLO Figure 2
The inhibitors of apoptosis (IAPs) regulate expression levels of Smac/DIABLO. Smac: Smac/DIABLO. IAPs 
downregulate Smac/DIABLO by ubiquitination and proteasomal degradation. XIAP, c-IAP1 and c-IAP2 action is mediated by 
their RING domain. Smac/DIABLO degradation by XIAP is inhibited when the protein NADE is associated with them. Survivin 
inhibits the release of Smac/DIABLO from mitochondria after apoptotic stimuli. In addition, Survivin prevents Smac/DIABLO 
degradation in the cytosol.Journal of Experimental & Clinical Cancer Research 2008, 27:48 http://www.jeccr.com/content/27/1/48
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